ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,610Medicare Part D Prescriptions Filled, Including Refills

Rank: 19 out of 623

$514K Total Retail Price of All Prescriptions

Rank: 34 out of 623

330 Patients Receiving at Least One Drug in Part D
37%Patients 65 Years and Older
85% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

34% of this provider’s 330 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

20% of this provider’s 330 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 4,054 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

17% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $66 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
SIMVASTATIN 536 255 1 2
LISINOPRIL 489 218 2 1
OXYCODONE HCL 397 99 S2 3 30
MELOXICAM 375 121 4 50
TRAMADOL HCL 288 69 5 15
METFORMIN HCL 268 134 6 6
OMEPRAZOLE 267 69 7 7
ZOLPIDEM TARTRATE 229 67 8 22
HYDROCODONE-ACETAMINOPHEN 225 89 S3 9 17
LEVOTHYROXINE SODIUM 211 119 10 4
WARFARIN SODIUM 179 85 11 14
CLONIDINE HCL 168 34 12 55
HYDROCHLOROTHIAZIDE 167 104 13 8
TRAZODONE HCL 165 23 14 36
METOPROLOL TARTRATE 159 107 15 9
FUROSEMIDE 157 75 16 5
CYCLOBENZAPRINE HCL 156 0 R 17 65
ATORVASTATIN CALCIUM 148 79 18 10
OXYCODONE-ACETAMINOPHEN 146 45 S2 19 42
ATENOLOL 139 78 20 12
ALENDRONATE SODIUM 134 104 21 37
CITALOPRAM HBR 126 12 22 21
FELODIPINE ER 121 48 23 154
PREDNISONE 109 34 24 40
AMLODIPINE BESYLATE 108 57 25 3
FLUTICASONE PROPIONATE 101 34 26 29
SPIRIVA 101 67 26 58
LANTUS 97 27 28 41
RANITIDINE HCL 96 43 29 23
GABAPENTIN 92 14 30 18
ADVAIR DISKUS 85 43 31 39
ENDOCET 84 28 S2 32 123
MORPHINE SULFATE ER 80 0 S2 33 114
SULFAMETHOXAZOLE-TRIMETHOPRIM 77 31 34 78
POTASSIUM CHLORIDE 76 41 35 24
LOVASTATIN 73 54 36 25
DOXEPIN HCL 68 0 37 208
IBUPROFEN 68 12 37 68
METOPROLOL SUCCINATE 67 16 39 13
FLUOXETINE HCL 66 23 40 84
CRESTOR 66 27 40 28
PRAVASTATIN SODIUM 65 25 42 11
CLOPIDOGREL 65 47 42 34
OXYCODONE HCL-ACETAMINOPHEN 64 15 S2 44 113
GLIPIZIDE 62 45 45 33
TRIAMCINOLONE ACETONIDE 61 24 46 130
CARVEDILOL 61 44 46 32
VENTOLIN HFA 60 0 48 92
NEXIUM 60 26 48 43
CARISOPRODOL 57 0 R 50 121
KLOR-CON M20 56 18 51 62
INSULIN SYRINGE 52 0 52 80
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 20, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.